ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
University of Washington at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
University of Washington takes part in 5 sessions at ESMO 2026 in Madrid. Its program centres on HER2-positive and HER2-low breast cancer, from early-stage to first-line metastatic treatment, and also covers urothelial cancer. It presents final results of a trial giving T-DXd before surgery, with or without anastrozole or in sequence with chemotherapy, in HER2-low, hormone receptor-positive early breast cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
University of Washington Seattle, WA | |
Public research university in Seattle, Washington, with a school of medicine. | Abstract Fri Oct 23 13:30–13:40 Chair Sat Oct 24 08:30–10:00 Talk Sun Oct 25 10:55–11:15 Satellite Sun Oct 25 13:05–13:20 Satellite Sun Oct 25 13:20–13:35 Satellite Sun Oct 25 13:35–13:50 Satellite Sun Oct 25 13:50–14:05 Satellite Sun Oct 25 13:50–14:05 Redefining the standard across invasive urothelial carcinoma Genitourinary cancers Satellite Sun Oct 25 14:05–14:30 Questions, Take-Home Learnings, and Evaluation Breast cancer Satellite Sun Oct 25 14:23–14:28 Audience Q&A: Advanced urothelial cancer Genitourinary cancers |
Find decision makers at University of Washington
Tell us what you sell and we’ll find the people at University of Washington most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction